New blood test may predict Alzheimer's risk

Dr. Jeremy Koppel, from the Litwin-Zucker Center, discusses a caller humor trial that could foretell Alzheimer's hazard wrong 5-10 years.

Dr. Jeremy Koppel, co-director of the Litwin-Zucker Center, discusses a caller humor trial susceptible of predicting Alzheimer's hazard up to 10 years successful advance. The trial identifies elevated levels of a tau macromolecule biomarker, P-tau217, indicating a higher likelihood of cognitive decline. Koppel highlights its imaginable for aboriginal diagnosis and knowing Alzheimer's progression.